Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep;20(3):182-7.
doi: 10.4103/0973-1075.138386.

Safety and efficacy of oral transmucosal fentanyl citrate compared to morphine sulphate immediate release tablet in management of breakthrough cancer pain

Sushma Bhatnagar  1 , Saraswathi Devi  2 , Nk Vinod  3 , Pn Jain  4 , G Durgaprasad  5 , Sanjaykumar H Maroo  6 , Ketan R Patel  7
Affiliations

Safety and efficacy of oral transmucosal fentanyl citrate compared to morphine sulphate immediate release tablet in management of breakthrough cancer pain

Sushma Bhatnagar et al. Indian J Palliat Care. 2014 Sep.

Abstract

Aim: To compare the efficacy and safety of oral transmucosal fentanyl citrate (OTFC) and oral morphine in Indian patients with breakthrough episodes of cancer pain.

Materials and methods: In this randomized, open label, active controlled, clinical study, total 186 patients who regularly experienced 1-4 episodes of breakthrough cancer pain (BTCP) daily, over the persistent pain controlled by taking oral morphine 60 mg/day or its equivalent were randomized to receive either OTFC 200 mcg or oral morphine 10 mg for the treatment of BTCP for 3 days. Improvement in pain as determined by numerical rating scale (NRS) at 5, 15, 30, and 60 minutes of drug administration and percentage of BTCP episodes showing reduction in pain intensity by >33% at 15 minutes were primary efficacy endpoints. Secondary efficacy endpoints were requirement for rescue analgesia and global assessment by physician and patient. Data of both treatment groups were analysed by appropriate statistical test using software, STATISTICA, version 11.

Results: Patients treated with OTFC experienced significantly greater improvement in pain intensity of breakthrough episodes compared to those treated with oral morphine at all assessment time points (P < 0.0001). 56% of breakthrough pain episodes treated with OTFC showed a greater than 33% reduction in pain intensity from baseline at 15 minutes compared to 39% episodes treated with oral morphine (P < 0.0001). Patient's and physician's global assessment favoured OTFC than oral morphine (P < 0.0001). Requirement of rescue analgesia in both the study groups was similar (P > 0.05). Both study drugs were well tolerated.

Conclusions: OTFC was found to provide faster onset of analgesic effect than immediate release oral morphine in management of breakthrough cancer pain.

Keywords: Breakthrough cancer pain; Morphine; Numeric rating scale; Oral transmucosal fentanyl citrate.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The study is sponsored by Troikaa Pharmaceuticals Ltd

Figures

Figure 1
Figure 1
Patient disposition flow chart (n is the number of patients)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Mishra S, Bhatnagar S, Chaudhary P, Singh SP. Breakthrough cancer pain: Review of prevalence, characteristics and management. Indian J Palliat Care. 2009;15:14–8. - PMC - PubMed
    1. Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, et al. Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR) Pain. 2001;91:123–30. - PubMed
    1. Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev. :CD004311. - PubMed
    1. Webster LR, Chun SY, Reinking J, Stegman M, Taylor D. Oral transmucosal fentanyl citrate use in chronic No cancer pain: A retrospective survey. [Last accessed on 2013 April 4]. Available from: http://www.crilifetree.com/media/abstracts/ORAL%20TRANSMUCOSAL%20FENTANY... .
    1. Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: The challenge of its dosing. Crit Rev Oncol Hematol. 2011;80:460–5. - PubMed